1Eijkelkamp WB ,et al. Albuminufia is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints inNIDDM with the Angiotensin 1I Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol,2007,18 : 1540 - 1546.
2Muller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol, 2006,1: 221 - 228.
3Li YC Inhibition of rennin. An updated review of the development of rennin inhibitors. Curr Opin Investig Drugs,2007,8:750 -757.
4Lavoie JL, Sigmund CD. Minireview : overview of the reninangiotensin systeman endocrine and paracrine system. Endocrinology, 2003, 144:2179 -2183.
5Paul M, Poyan Mehr A, Kreutz R. Physiology of local reninangiotensin systems. Physiol Rev ,2006,86:747 - 803.
6Chan JC, Ko GT, Leung DH, et al. Long - term effects of angiotensin converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int ,2000,57:590 -600.
7Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective of the angiotensin - receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med ,2001,345 :851 -860.
8Parving HH, Lehnert H, Brochner - Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med, 20011345:870 -878.
9VAndersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin lI receptor blockade in type I diabetic patients with diabetic nephropathy. Kidney Int,2000,57:601 -606.
10Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension, 2002,39 : 129 - 134.
